ÌÇÐÄÆƽâ°æ

Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

October 2024

Region

United States

Survey time period

As of Q4 2024

Supplementary notes

WAC: Wholesale acquisition cost.

Citation formats

Adalimumab wholesale acquisition cost in the U.S. 2024

Published by A. Minhas, Nov 29, 2024

As of year-end 2024, Humira (adalimumab) biosimilars Hadlima, Yusimry and Simlandi offered the largest cost savings compared to the original, at an percent lower WAC. Other biosimilars offered dual or multiple pricing options, where the WAC can vary heavily. Private label adalimumab also had a significantly lower WAC compared to the original, except for Cordavis' Humira. This statistic depicts the wholesale acquisition cost (WAC) of adalimumab in the United States, comparing originator drug Humira (AbbVie) to its biosimilars, as of Q4 2024. 

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars in the U.S. "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars in the U.S.

Global Overview & Context

6

Competitive Landscape

5

Market Penetration & Entry Pipeline

5

Pricing & Payer Economics

6

Biosimilar Market Acceleration

6

Further Content: You might find this interesting as well

Topics

Generics and biosimilars in the U.S.Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsDrug pricing in the U.S.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.